Clinical Trials

480 enrolled

Advanced Malignant Solid Tumors

NCT07481058 2026-03-18

A Study of KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy as First-line Treatment in Patients With Advanced Esophageal Cancer

60 enrolled

Esophageal Squamous Cell Carcinoma

NCT05738694 2026-03-17

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Phase 3 Recruiting

298 enrolled

Carcinoma, Renal Cell

NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

146 enrolled

Muscle Invasive Bladder Cancer (MIBC)

NCT07469956 2026-03-13

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

30 enrolled

Pancreatic Neoplasms

NCT05798845 2026-03-11

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

124 enrolled

NSCLC

NCT04651127 2026-03-10

Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer

Phase 1/2 Terminated

5 enrolled

Phase 1 Active not recruiting

Uterine Cervical Neoplasms

NCT05707910 2026-03-09

Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

6 enrolled

Tumor-Agnostic

Neoplasms

NCT07209189 2026-03-09

(NeoScorch HN)

75 enrolled

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

NCT07457359 2026-03-09

NEOTRIO-2

18 enrolled

Triple Negative Breast Neoplasms

NCT06114940 2026-03-05

PLUTO

Phase 2 Terminated

17 enrolled

Carcinoma, Renal Cell

NCT06975293 2026-03-05

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

DermatologicGynecologicHead & NeckThoracic

188 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Endometrial Neoplasms

NCT06208826 2026-03-03

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

268 enrolled

Head and Neck Neoplasms

NCT06719700 2026-03-03

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

47 enrolled

Small Cell Lung Carcinoma

NCT06457503 2026-03-02

TRANSPARENT

Phase 4 Recruiting

100 enrolled

Nasopharyngeal Neoplasms

NCT06657144 2026-03-02

A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Phase 1 Recruiting

154 enrolled

Phase 1/2 Not yet recruiting

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07277322 2026-03-02

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

24 enrolled

Phase 2 Active not recruiting

Colorectal Neoplasms

NCT05888402 2026-02-27

InTRist

50 enrolled

Local Advanced Non-small Cell Lung Cancer

NCT07281716 2026-02-19

Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC

24 enrolled

Colorectal Neoplasms

NCT04918186 2026-02-12

IPROC

60 enrolled

Ovarian Neoplasms

NCT07281976 2026-02-12

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

220 enrolled

Triple Negative Breast Neoplasms

NCT06592599 2026-02-10

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

24 enrolled

Nasopharyngeal Carcinoma

NCT07290621 2026-02-06

Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

30 enrolled

Oropharyngeal Neoplasms

NCT07392736 2026-02-06

A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

228 enrolled

Solid Tumor

NCT06679985 2026-02-05

A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

72 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05518045 2026-02-04

A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors

392 enrolled

Phase 1/2 Active not recruiting

Advanced Solid Tumor

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

500 enrolled

Solid Cancer

NCT07383818 2026-02-03

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

111 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT06952621 2026-01-30

TD-NEOE3V3

390 enrolled

Phase 2/3 Active not recruiting

Esophageal Squamous Cell Carcinoma

NCT06984588 2026-01-30

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

450 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07378306 2026-01-30

FACT-TN

80 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07376499 2026-01-29

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

31 enrolled

Phase 3 Not yet recruiting

Small Cell Lung Carcinoma

NCT07371897 2026-01-28

SHINE

154 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06281405 2026-01-27

TORCH-iTNT

192 enrolled

Locally Advanced Rectal Cancer

NCT07363330 2026-01-26

A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer

32 enrolled

Phase 3 Not yet recruiting

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

NCT07362186 2026-01-23

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

400 enrolled

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

120 enrolled

NSCLC

NCT07342322 2026-01-15

A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma

25 enrolled

Sarcoma

NCT06682195 2026-01-14

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

35 enrolled

Triple Negative Breast Neoplasms

NCT07340515 2026-01-14

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

Phase 3 Recruiting

300 enrolled

Nasopharyngeal Carcinoma

NCT04284488 2026-01-08

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Phase 1/2 Terminated

40 enrolled

Phase 1 Not yet recruiting

Advanced Solid Tumor

NCT06283134 2026-01-07

A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

60 enrolled

Phase 2 Active not recruiting

Colorectal Neoplasms

NCT06416696 2026-01-02

Toripalimab for High-risk Locally Advanced Cervical Cancer

57 enrolled

Uterine Cervical Neoplasms

NCT07314723 2026-01-02

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

90 enrolled

Carcinoma, Transitional Cell

NCT07279597 2025-12-19

A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer

45 enrolled